AbstractTreatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while many studies have reported on gefitinib-related interstitial lung disease (ILD), less published data are available regarding erlotinib-induced ILD. Here, we report a case of pulmonary adenocarcinoma who developed ILD due to gefitinib initially and erlotinib thereafter. The two episodes of ILD were treated successfully with the discontinuation of the tyrosine kinase inhibitors and high-dose intravenous corticosteroids
Gefitinib is effective in the treatment of non-small-cell lung cancer (NSCLC), especially in the Asi...
Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns ranging from ...
BackgroundData comparing the incidence and pattern of interstitial lung disease (ILD) in non-small c...
Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while...
AbstractTreatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. Howeve...
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibito...
Objective. To report a case of who a patient developed clinical and radiographical evidence of inter...
SummaryAlthough pulmonary toxicity associated with gefitinib, an epidermal growth factor receptor in...
AbstractThe use of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is cons...
Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the in...
INTRODUCTION: Erlotinib is an agent in the class of oral epidermal growth factor receptor (EGFR) tyr...
Erlotinib is one of the most widely used tyrosine kinase inhibitor targeting human epidermal growth ...
Gefitinib, an orally active, selective inhibitor of epidermal growth factor-receptor tyrosine kinase...
Gefitinib, an orally active, selective inhibitor of epidermal growth factor-receptor tyrosine kinase...
AbstractIntroductionAlthough interstitial lung disease (ILD) is a known serious adverse effect of ep...
Gefitinib is effective in the treatment of non-small-cell lung cancer (NSCLC), especially in the Asi...
Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns ranging from ...
BackgroundData comparing the incidence and pattern of interstitial lung disease (ILD) in non-small c...
Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while...
AbstractTreatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. Howeve...
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibito...
Objective. To report a case of who a patient developed clinical and radiographical evidence of inter...
SummaryAlthough pulmonary toxicity associated with gefitinib, an epidermal growth factor receptor in...
AbstractThe use of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is cons...
Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the in...
INTRODUCTION: Erlotinib is an agent in the class of oral epidermal growth factor receptor (EGFR) tyr...
Erlotinib is one of the most widely used tyrosine kinase inhibitor targeting human epidermal growth ...
Gefitinib, an orally active, selective inhibitor of epidermal growth factor-receptor tyrosine kinase...
Gefitinib, an orally active, selective inhibitor of epidermal growth factor-receptor tyrosine kinase...
AbstractIntroductionAlthough interstitial lung disease (ILD) is a known serious adverse effect of ep...
Gefitinib is effective in the treatment of non-small-cell lung cancer (NSCLC), especially in the Asi...
Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns ranging from ...
BackgroundData comparing the incidence and pattern of interstitial lung disease (ILD) in non-small c...